MedPath

Takeda Pharmaceutical Company Ltd

🇸🇪Sweden
Ownership
-
Established
1925-01-01
Employees
-
Market Cap
$47.5B
Website
http://www.takeda.co.jp/
Clinical Trials
Related News

TASALL - TachoSil® Against Liquor Leak

Phase 3
Completed
Conditions
Cerebrospinal Fluid Leaks
Interventions
Procedure: TachoSil®
Procedure: Current Practice
First Posted Date
2011-05-18
Last Posted Date
2014-07-25
Lead Sponsor
Takeda
Target Recruit Count
726
Registration Number
NCT01355627
Locations
🇸🇪

Nycomed Investigational Site, Stockholm, Sweden

Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

Phase 3
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
Drug: Vortioxetine
First Posted Date
2011-05-17
Last Posted Date
2014-11-11
Lead Sponsor
Takeda
Target Recruit Count
366
Registration Number
NCT01355081

Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia

Phase 3
Completed
Conditions
Hypertriglyceridemia
Interventions
Drug: omega-3-acid ethyl esters 90 (TAK-085)
Drug: Eicosapentaenoic acid-ethyl (EPA)
First Posted Date
2011-05-10
Last Posted Date
2016-09-20
Lead Sponsor
Takeda
Target Recruit Count
503
Registration Number
NCT01350999

Efficacy of TAK-085 in Participants With Hypertriglyceridemia

Phase 3
Completed
Conditions
Hypertriglyceridemia
Interventions
Drug: Omega-3-acid ethyl esters 90 (TAK-085)
Drug: Eicosapentaenoic acid-ethyl (EPA-E)
First Posted Date
2011-05-10
Last Posted Date
2016-09-20
Lead Sponsor
Takeda
Target Recruit Count
611
Registration Number
NCT01350973

Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan

Phase 2
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Alogliptin and glimepiride
Drug: Alogliptin and metformin
First Posted Date
2011-03-18
Last Posted Date
2012-08-16
Lead Sponsor
Takeda
Target Recruit Count
576
Registration Number
NCT01318135

Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan

Phase 2
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Alogliptin and pioglitazone
First Posted Date
2011-03-18
Last Posted Date
2012-02-03
Lead Sponsor
Takeda
Target Recruit Count
336
Registration Number
NCT01318122

Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan

Phase 2
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Alogliptin and metformin
Drug: Metformin
First Posted Date
2011-03-18
Last Posted Date
2012-02-03
Lead Sponsor
Takeda
Target Recruit Count
288
Registration Number
NCT01318109

Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan

Phase 2
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Alogliptin and glimepiride
Drug: Glimepiride
First Posted Date
2011-03-18
Last Posted Date
2012-02-03
Lead Sponsor
Takeda
Target Recruit Count
312
Registration Number
NCT01318083

Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan

Phase 2
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Alogliptin and pioglitazone
Drug: Pioglitazone
First Posted Date
2011-03-18
Last Posted Date
2012-02-03
Lead Sponsor
Takeda
Target Recruit Count
339
Registration Number
NCT01318070

A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis

Phase 1
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Placebo
Drug: namilumab (MT203)
First Posted Date
2011-03-17
Last Posted Date
2015-08-20
Lead Sponsor
Takeda
Target Recruit Count
24
Registration Number
NCT01317797
Locations
🇳🇱

Nycomed Investigational Site, Leids, Netherlands

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy